*	OR T3 T4
R1	AND Arg1:T5 Arg2:T6	
*	OR T9 T8 T10 T11 T7
R2	AND Arg1:T11 Arg2:T12	
R3	Has_value Arg1:T16 Arg2:T17	
T1	Drug 24 31	Dapsone
T2	Non-query-able 42 124	The subject or any of their healthcare providers is aware of the subjects HLA type
T3	Condition 151 195	Glucose-6-phosphate dehydrogenase deficiency
T4	Condition 199 233	methemoglobin reductase deficiency
T5	Condition 249 266	contraindications
T6	Drug 286 293	Dapsone
T7	Condition 387 400	renal failure
T8	Condition 377 382;393 400	liver failure
T9	Condition 370 375;393 400	heart failure
T10	Condition 402 423	major organ allograft
T11	Condition 425 435	malignancy
T12	Procedure 457 469	chemotherapy
T13	Non-query-able 647 866	Any laboratory abnormality at Screening which, in the opinion of the Investigator, should preclude the subject's participation in the study [alanine aminotransferase (ALT), glutamic oxaloacetic transaminase(ALT), et al)
T14	Pregnancy_considerations 870 914	regnant women or women who are breastfeeding
T15	Non-query-able 917 1049	Subject is, in the opinion of the Investigator, unable to complete the 6 week Observation period and the EPT assessments as required
T16	Measurement 1074 1084	HLA-B*1301
T17	Value 1054 1062	positive
